Connexin 43 (Cx43) gap junctions are hypothesized to play a key role in many aspects of vascular function. In an effort to evaluate the importance of connexins in vascular function we took advantage of the fact that a Cx43-LacZ fusion protein has been reported to effectively reduce dye transfer in NIH 3T3 fibroblasts by acting as a dominant negative construct. We explored the use of this dominant negative construct in cultured vascular smooth muscle (VSM) cells and in transgenic mice. We examined the viability of cultured VSM cells expressing the Cx43-LacZ fusion protein under the control of a cytomegalovirus promoter. We also selectively expressed the dominant negative construct in the endothelial cells of transgenic mice under the control of a Tie 2 promoter. Transient transfection of cultured VSM cells led to good initial expression of the Cx43-LacZ fusion protein as evidenced by X-gal staining. Following 10 days of G418 selection, 300 cell clones were examined. None expressed the fusion protein, based on X-gal staining and Western blot analysis, but all contained the transgene, based on PCR analysis. The fusion protein was expressed in a few isolated cells, suggesting that cell division was inhibited by the fusion protein. In agreement with this finding was the fact that expression of the Cx43-LacZ fusion protein was not observed in any of seven Tie 2-Cx43-LacZ transgenic mouse lines. Moreover, a very low yield of mice carrying the transgene was observed (7/136; 5.1%). Analysis of 65 embryos at embryonic day 11.5 showed similar results. These data strongly suggest that the expression of the Cx43-LacZ fusion protein prevents the formation of both stable clones and transgenic animals. This may be due to a cytotoxic effect of the dominant negative construct or to the fact that successful cell propagation is not possible if gap junctional transmission is completely blocked.

Animals↗

PubMedDate not supplied

Access of blood-borne vasoconstrictors to the arteriolar smooth muscle.

In vitro experiments have shown that luminally applied water-soluble vasoactive materials have limited access to arteriolar smooth muscle cells, and as a result, the responses to such agents applied luminally are less than the responses to those applied adventitially. To determine the extent to which this 'compartmentation' influences arteriolar responsiveness to blood-borne water-soluble vasoconstrictors in vivo, we applied phenylephrine, vasopressin and angiotension II to arterioles in the hamster cheek pouch both by luminal perfusion, and by topical application to the arteriolar smooth muscle via micropipettes. The arterioles were about 2 orders of magnitude more sensitive to these water-soluble vasoconstrictors when they were applied topically than when they were applied luminally. In contrast, the arterioles were almost equally sensitive to the lipid-soluble alpha 1-adrenoceptor agonist SKF 89748-A applied by either route. The venular wall appears to be much less effective as a barrier than the arteriolar endothelium. Phenylephrine and vasopressin both elicited large arteriolar constrictions when perfused through venules in close proximity to the arteriole, and these constrictions were larger than those observed when the drug was applied to the arteriole's own lumen. Our observations confirm that the arteriolar endothelium can inhibit the direct access of water-soluble blood-borne agents to the arteriolar smooth muscle in vivo, and they suggest that the capillaries and venules could be the primary routes of access for water-soluble agents from the blood to the arteriolar smooth muscle.

Angiotensin II↗

PubMedDate not supplied

Vasoactive effects of basic and acidic fibroblast growth factors in hamster cheek pouch arterioles.

Fibroblasts growth factors (FGFs) exhibit well-known angiogenic actions, but there is some controversy about whether they have vasoactive effects on blood vessels which might contribute to angiogenesis per se. To clarify this, changes in arteriolar diameter were recorded during observation by videomicroscopy of 3rd- and 4th (terminal)-order arterioles (resting diameters 22.5 +/- 0.5 microns and 14.4 +/- 0.3 microns, respectively) in the hamster cheek pouch in response to FGF application. Recombinant human bFGF (basic) and aFGF (acidic) were applied from micropipettes positioned 5-10 microns from the adventitial surface of vessels. Maximum vasodilator effects of adenosine (10(-4) M) applied in a similar way were also observed. Adenosine increased the diameters of 4th-order arterioles by 37.2 +/- 3.8% and those of 3rd-order arterioles by 38.7 +/- 2.7. bFGF produced vasodilatation (threshold dose 0.1 ng ml-1) in both classes of arterioles, while aFGF produced dose-dependent constriction (threshold dose 0.01 ng ml-1). A maximal dilator effect in 4th-order arterioles was obtained with 100 ng ml-1 bFGF, when diameters reached 82.6 +/- 2.4% of those with adenosine. Maximal constrictor effect (-48.2 +/- 5.6% of resting diameter) occurred with a dose of 100 ng ml-1 aFGF. Vehicle alone (MOPS or bicarbonate buffer used as solvents for FGFs) had no effect. As vasoconstrictors are known to stimulate growth of smooth muscle cells while dilators stimulate growth of endothelial cells, it is possible that the opposing vasoactivities demonstrated for aFGF and bFGF are linked with their selective mitogenicity for smooth muscle and endothelial cells, respectively, and contribute to their angiogenic actions.

Adenosine↗